European Pharmaceutical Review

MARCH 21, 2023

AstraZeneca and MSD’s treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in first-line mCRPC.

Patients 92

Patients Medicine Healthcare Healthcare 92

Pharmaceutical Technology

APRIL 17, 2024

Everolimus is under clinical development by Novartis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

52

52

European Pharmaceutical Review

DECEMBER 5, 2022

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death.

Food and Drug Administration 98

Food and Drug Administration Safety Food Medical 98

Pharmacy Times

NOVEMBER 7, 2023

With precision medicine, patients undergoing treatment are living longer without disease recurrence or progression and with fewer adverse effects, resulting in preservation of quality of life.

Medicine 49

Medicine Patients 49

Medgadget

NOVEMBER 1, 2022

Avenda Health , a medtech company based in Santa Monica, California has developed the FocalPoint ablation system, an AI-powered prostate cancer therapy. Conn Hastings, Medgadget: Please give us a basic overview of current approaches to treat prostate cancer, and their shortcomings. annual biopsies/monitoring).

Patients 89

Patients FDA Management Marketing 89

European Pharmaceutical Review

AUGUST 17, 2022

The MHRA has also issued a licence in Great Britain for Locametz ® (gozetotide) which, after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of PSMA-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer. percent), dry mouth (38.8

Medicine 114

Medicine Patients Consulting Marketing 114

Pharmaceutical Technology

FEBRUARY 7, 2024

Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.

52

52

Pharmacy Times

SEPTEMBER 28, 2022

There were approximately 250,000 new cases of prostate cancer identified in the United States in 2021, which is considered approximately 13% of all cancer cases.

47

47

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. The post NICE says no to Lynparza in prostate cancer, creating UK access divide appeared first on.

Manufacturing 109

Manufacturing Patients Marketing 109

Pharmaceutical Technology

JUNE 1, 2023

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD ’s Lynparza (olaparib), with standard therapies for treating BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is the second-most common cancer reported in men.

Food and Drug Administration 97

Food and Drug Administration FDA Food Safety 97

pharmaphorum

NOVEMBER 27, 2022

There are over 52,000 cases of prostate cancer each year in the UK alone, with over 15,000 new cases of metastatic prostate cancer confirmed annually. There are over 52,000 cases of prostate cancer each year in the UK alone, with over 15,000 new cases of metastatic prostate cancer confirmed annually.

Food and Drug Administration 79

Food and Drug Administration Medicine Consulting Patients 79

European Pharmaceutical Review

DECEMBER 21, 2022

Positive Phase III trial results for metastatic castration-resistant prostate cancer. The safety and tolerability of Lynparza in combination with abiraterone in PROpel was in line with that observed in prior clinical trials and the known profiles of the individual medicines.

Medicine 95

Medicine Patients Safety Pharmaceutical 95

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Food and Drug Administration 105

Food and Drug Administration Food Marketing Manufacturing 105

Pharmaceutical Technology

AUGUST 8, 2022

The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients. in trial subjects versus those who received ADT plus docetaxel.

Food and Drug Administration 98

Food and Drug Administration FDA Safety Food 98

European Pharmaceutical Review

APRIL 4, 2024

Benefit of the advanced Ga-68 radiolabelling technology According to RLS, Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a major role in the diagnosis and treatment planning for patients with neuroendocrine tumours and prostate cancer.

Transportation 82

Transportation Distribution Healthcare Healthcare 82

Pharma Leaders

APRIL 25, 2023

The FDA has granted Fast Track designation to Lantheus and Point Biopharma’s 177Lu-PNT2002 for the treatment of metastatic castration-resistant prostate cancer. 117Lu-PNT2002 is currently under a phase 3 clinical trial setting, with enrollment complete and top-line data expected in the second half of this year.

Biopharma 52

Biopharma FDA Medical 52

Pharmaceutical Technology

FEBRUARY 19, 2024

AC-0176 is under clinical development by Accutar Biotechnology and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

FEBRUARY 7, 2024

CONV 01-alpha is under clinical development by Convergent Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

pharmaphorum

AUGUST 9, 2022

Magnetic resonance imaging (MRI) technology specialist Bot Image has won FDA approval for its artificial intelligence-powered software ProstatID, used for the detection and diagnosis of prostate cancer. The post FDA okays ProstatID software for detecting prostate cancer in MRI appeared first on.

FDA 83

FDA Training Medical 83

pharmaphorum

JANUARY 26, 2023

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co’s checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. It remains ongoing with updated results due in the coming months.

Side effects 59

Side effects Patients FDA 59

European Pharmaceutical Review

MARCH 6, 2024

Keren Haruvi, President Sandoz North America highlighted that denosumab is a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events. Wyost Similarly, Wyost 120 mg/1.7 mL (70 mg/mL) injection is a human monoclonal antibody designed to bind to the RANKL protein.

Food and Drug Administration 92

Food and Drug Administration Medicine FDA Food 92

European Pharmaceutical Review

AUGUST 14, 2023

The US Food and Drug Administration (FDA) has approved Janssen’s Akeega (niraparib and abiraterone acetate), for the treatment of adult patients BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). acquired by GlaxoSmithKline in 2019) for exclusive rights to niraparib in prostate cancer treatment.

FDA 52

FDA Food and Drug Administration Medicine Prospecting 52

Pharmaceutical Technology

FEBRUARY 27, 2023

Finnish pharmaceutical firm Orion has received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide plus androgen deprivation therapy (ADT) along with docetaxel to treat metastatic prostate cancer. It also demonstrated consistent benefits across clinically relevant secondary endpoints of the trial.

Medicine 52

Medicine Safety Pharmaceutical Patients 52

Pharmaceutical Technology

APRIL 6, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending AstraZeneca’s olaparib to treat early breast cancer and metastatic prostate cancer. It also updates NICE’s recommendation for olaparib for prostate cancer patients with BRCA1 or BRCA2 mutations.

Medicine 52

Medicine Patients 52

Pharmaceutical Technology

FEBRUARY 7, 2024

Cyclosam is under clinical development by QSAM Therapeutics and currently in Phase I for Metastatic Prostate Cancer.

40

40

pharmaphorum

DECEMBER 5, 2022

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Medicine 59

Medicine Safety FDA Healthcare 59

European Pharmaceutical Review

DECEMBER 13, 2022

The European Commission (EC) has approved Pluvicto ® (lutetium (177Lu) vipivotide tetraxetan), the first targeted radioligand therapy commercially available for people with advanced prostate cancer. Clinical data that led to the European Commission’s approval. Additional regulatory approvals for Pluvicto ®.

Food and Drug Administration 59

Food and Drug Administration Food Patients Safety 59

Pharmaceutical Technology

DECEMBER 25, 2023

ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

JUNE 21, 2023

The US Food and Drug Administration (FDA) has granted approval to Pfizer’s Talzenna (talazoparib) along with Xtandi (enzalutamide) for prostate cancer. The combination therapy is indicated to treat homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) in adult patients.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Food 52

Pharmaceutical Technology

DECEMBER 21, 2023

PF-07220060 is under clinical development by Pfizer and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharma Leaders

MARCH 20, 2023

Orion has received approval from the Chinese National Medical Products Administration (NMPA) for darolutamide along with docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients. The NMPA granted the approval based on the positive results obtained from the Phase III ARASENS clinical trial of darolutamide.

Patients 52

Patients Medical 52

Pharmaceutical Technology

DECEMBER 5, 2023

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC).

40

40

Pharmaceutical Technology

DECEMBER 5, 2023

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC).

40

40

Pharmaceutical Technology

DECEMBER 22, 2023

Dresbuxelimab is under clinical development by Akeso and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).

40

40

pharmaphorum

AUGUST 4, 2022

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy studies can be a hit-and-miss affair. Lenvima combination.

Patients 90

Patients FDA 90

Pharmaceutical Technology

JANUARY 4, 2024

XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Prostate Cancer.

40

40

Pharmaceutical Technology

OCTOBER 25, 2023

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40